• Predicting Major Bleeding Risk in Extended VTE Anticoagulati

  2026-08-03

  This study introduces and validates the CHAP model—a streamlined clinical tool for predicting major bleeding risk during extended anticoagulation in patients with unprovoked or weakly provoked venous thromboembolism (VTE). Its findings support the use of modified risk scores to guide treatment duration, with implications for safer long-term VTE management.

• Tigecycline in Translational Research: Mechanisms, Models, a

  2026-08-02

  This thought-leadership article offers an advanced perspective for translational researchers on deploying Tigecycline—a flagship glycylcycline antibiotic—in the battle against multidrug-resistant pathogens. Drawing on recent molecular epidemiology, mechanistic insights, and practical workflow guidance, it establishes a strategic roadmap for next-generation antimicrobial research and clinical innovation.

• Cell Counting Kit-8 Plus: Scientific Advances and Autophagy

  2026-08-01

  Discover how Cell Counting Kit-8 Plus transforms cell viability quantification with advanced WST-8 chemistry. This article provides a deeper mechanistic analysis and connects assay optimization to the latest autophagy research, offering novel guidance beyond standard protocols.

• DFO (9H-1,8-Diazafluoren-9-one): Precision in Forensic Finge

  2026-07-31

  DFO (9H-1,8-Diazafluoren-9-one) is a validated fluorescent dye for forensic latent fingerprint detection on porous substrates. Its amino acid reactivity and high fluorescence yield enable sensitive, reproducible results in investigative workflows. Supplied by APExBIO, DFO is characterized by high purity and robust protocol compatibility.

• Anlotinib Hydrochloride: Deep Dive into Multi-Target Angioge

  2026-07-31

  Explore the unique pharmacology and research applications of Anlotinib hydrochloride, a potent multi-target tyrosine kinase inhibitor. This article offers an in-depth perspective on its mechanistic selectivity, pharmacokinetics, and optimized use in endothelial cell assays, distinguishing itself from standard assay guides.

• HyperFusion™ DNA Polymerase: Precision PCR for Neurodegenera

  2026-07-30

  Discover how HyperFusion high-fidelity DNA polymerase advances neurodegeneration research by enabling accurate, robust PCR amplification—even for challenging GC-rich or long templates. This article uniquely connects enzyme selection with emerging insights in neuronal proteostasis and assay design.

• CAY10499: Lipase Inhibition for Next-Gen Immunometabolic Res

  2026-07-30

  Explore the mechanistic rationale and translational promise of CAY10499, a potent inhibitor of human hormone sensitive lipase and monoglyceride lipase, in decoding tumor microenvironment reprogramming. This thought-leadership article synthesizes metabolic enzyme targeting, recent breakthroughs in extracellular vesicle-mediated immunosuppression, and actionable protocol strategies, positioning CAY10499 as a pivotal reagent for advanced immuno-oncology and metabolic disease modeling.

• p53/PUMA-Dependent Synthetic Lethality via WRN Inhibition in

  2026-07-29

  This study uncovers the mechanistic basis for synthetic lethality between Werner (WRN) helicase inhibition and mismatch repair deficiency in colorectal cancer. The findings demonstrate that WRN loss induces p53/PUMA-mediated apoptosis in microsatellite instability (MSI) colorectal cancer cells, establishing WRN as a promising DNA repair enzyme inhibitor target for p53-wildtype MSI CRCs.

• Smoothened Agonist (SAG): Strategic Leverage in Translationa

  2026-07-29

  This article provides translational researchers with an integrated, evidence-driven perspective on Smoothened Agonist (SAG) as a pivotal tool for Hedgehog pathway activation. By unpacking recent mechanistic insights—including teratogenicity and immune modulation—while offering practical protocol guidance and a forward-looking outlook, it positions APExBIO’s SAG as a gold-standard resource for developmental biology, regenerative medicine, and disease modeling.

• AZD3463: Advanced ALK/IGF1R Inhibitor Workflows in Neuroblas

  2026-07-28

  AZD3463, a dual ALK/IGF1R inhibitor, enables precise pathway dissection and optimized combination therapies in neuroblastoma research. This guide delivers actionable protocols, troubleshooting strategies, and novel insights drawn from state-of-the-art studies and validated use-cases.

• Myotubularin 2-Mediated Regulation of Autophagy at ER Exit S

  2026-07-28

  This study uncovers how Arabidopsis Myotubularin 2 (MTM2), a PtdIns3P phosphatase, interacts with COPII component SEC23A to restrict autophagy at ER exit sites. The findings establish a mechanistic link between PtdIns3P turnover, autophagosome formation, and ER-to-Golgi trafficking, providing new insights into the cellular balance of degradation and secretion during plant stress adaptation.

• LNP-mRNA Vaccine Targeting C. psittaci MOMP Elicits Protecti

  2026-07-27

  A recent study demonstrates that a lipid nanoparticle-delivered mRNA vaccine encoding the major outer membrane protein (MOMP) of Chlamydia psittaci induces strong protective immune responses in BALB/c mice. The findings support the feasibility of mRNA vaccine platforms for respiratory zoonoses and provide practical parameters for future vaccine development.

• Butylated Hydroxyanisole (BHA): Applied Antioxidant Workflow

  2026-07-27

  Butylated hydroxyanisole (BHA) stands out as a synthetic antioxidant for rigorous oxidative stress research, providing reproducibility and sensitivity in ROS modulation and apoptosis pathway studies. This article details advanced experimental workflows, highlights protocol optimization, and translates the latest reference findings into actionable guidance for cell and molecular scientists.

• Rucaparib (AG-014699): Advanced Workflows in DNA Damage Rese

  2026-07-26

  Rucaparib (AG-014699) is redefining DNA damage response research by enabling precise inhibition of PARP1 and robust radiosensitization, especially in challenging prostate cancer models. This guide highlights optimized workflows, troubleshooting strategies, and actionable insights rooted in cutting-edge evidence and the latest advances from APExBIO.

• Mdivi-1: Strategic Control of Mitochondrial Dynamics in Tran

  2026-07-25

  Explore how Mdivi-1, a selective DRP1 inhibitor from APExBIO, empowers translational researchers with precision tools to dissect mitochondrial fission, apoptosis, and neuroprotection. This article integrates mechanistic insights, protocol strategies, and cross-study evidence—bridging foundational biology to disease models and translational workflows.

448 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page